IXICO Beheer

Beheer criteriumcontroles 2/4

De CEO IXICO is Bram Goorden, benoemd in Aug2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.57% van de aandelen van het bedrijf, ter waarde € 78.78K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 4 jaar.

Belangrijke informatie

Bram Goorden

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	7.3yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

CEO

Bram Goorden (50 yo)

less than a year

Tenure

Mr. Bram Goorden, M.Sc., serves as Chief Executive Officer of IXICO plc since August 19, 2024. He served as Chief Operating Officer and Senior Vice President at SOPHiA GENETICS SA since August 2020 until 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Grant Nash	CFO, Company Secretary & Executive Director	5.6yrs	UK£216.00k	0.55% € 75.6k
Bram Goorden	Chief Executive Officer	less than a year	geen gegevens	0.57% € 78.8k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	20.8yrs	geen gegevens	geen gegevens
Derek Lionel Hill	Co-Founder and President of Regulatory Science & External Relations	7.3yrs	UK£387.01k	geen gegevens
David Hawkes	Co-Founder & Member of Scientific Advisory Board	20.8yrs	geen gegevens	geen gegevens
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	20.8yrs	geen gegevens	geen gegevens
Mark Austin	Director of Technology	no data	geen gegevens	geen gegevens
Robin Wolz	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Hannah Esfahanian	HR Manager	no data	geen gegevens	geen gegevens
John Hall	Senior Vice President of Business Development	8.5yrs	geen gegevens	geen gegevens
Lammert Albers	Chief Business Officer	5.1yrs	geen gegevens	geen gegevens
Alison Howie	Chief Product Officer	6.4yrs	geen gegevens	geen gegevens

7.3yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PYPB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Grant Nash	CFO, Company Secretary & Executive Director	5.3yrs	UK£216.00k	0.55% € 75.6k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Hawkes	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dipti Amin	Independent Non-Executive Director	1.1yrs	geen gegevens	0.11% € 15.8k
Mark Warne	Independent Non-Executive Chair	8.2yrs	UK£31.00k	0.078% € 10.8k
Katherine Rogers	Senior Independent Non-Executive Director	2.8yrs	UK£31.00k	0.057% € 7.9k

4.0yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PYPB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

IXICO Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

IXICO plc, Annual General Meeting, Jan 25, 2024

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

IXICO plc, Annual General Meeting, Jan 27, 2023

Recent updates

IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024

New major risk - Share price stability

New major risk - Shareholder dilution

Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

New major risk - Revenue and earnings growth

IXICO plc to Report First Half, 2024 Results on May 21, 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

Full year 2023 earnings released: UK£0.024 loss per share (vs UK£0.021 profit in FY 2022)

IXICO plc, Annual General Meeting, Jan 25, 2024

IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023

New major risk - Market cap size

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

New major risk - Revenue and earnings growth

IXICO plc Provides Earnings Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022)

IXICO plc to Report First Half, 2023 Results on May 23, 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

Full year 2022 earnings released: EPS: UK£0.021 (vs UK£0.033 in FY 2021)

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Financial Year 2023

First half 2022 earnings released

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022

IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020)

Investor sentiment improved over the past week

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited

Investor sentiment improved over the past week

IXICO plc Announces Collaboration with Microsoft

Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial

IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc

New 90-day low: €0.98

IXICO Secures New Contract for £3.4 Million

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS UK£0.02

Revenue beats expectations

IXICO plc, Annual General Meeting, Jan 21, 2021

IXICO plc Announces £1.9 Million New Study Award

Market bids up stock over the past week

New 90-day high: €1.26

Market bids up stock over the past week

IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020

Market bids up stock over the past week

New 90-day high: €1.22

Market bids up stock over the past week

IXICO plc and NYU Langone Health Signs Agreement

IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease

Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance

Global Alzheimer's Platform Foundation Selects IXICO plc for Innovative Bio-Hermes Trial

New 90-day high - €0.94

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd